Furthermore, the anti‐PD‐1 antibody tislelizumab was also evaluated in conjunction with chemotherapy in advanced NSCLC patients in China across two separate randomized Phase 3 trials [45, 46]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.